

Robert Weissert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3015353/publications.pdf>

Version: 2024-02-01

131
papers

11,171
citations

47006

47
h-index

29157

104
g-index

136
all docs

136
docs citations

136
times ranked

11093
citing authors

#	ARTICLE	IF	CITATIONS
1	Upregulated Retinal Neurofilament Expression in Experimental Optic Neuritis. <i>Neuro-Ophthalmology</i> , 2022, 46, 215-219.	1.0	3
2	Editorial: Telemedicine During and Beyond COVID-19. <i>Frontiers in Public Health</i> , 2021, 9, 662617.	2.7	39
3	Emerging role of white matter lesions in cerebrovascular disease. <i>European Journal of Neuroscience</i> , 2021, 54, 5531-5559.	2.6	20
4	Leukoaraiosis severity and postâ€reperfusion outcomes in acute ischaemic stroke: A metaâ€analysis. <i>Acta Neurologica Scandinavica</i> , 2021, , .	2.1	17
5	Brain atrophy in acute ischaemic stroke patients treated with reperfusion therapy: a systematic review. <i>Acta Radiologica</i> , 2021, , 028418512110604.	1.1	3
6	The Effect of Coffee and Caffeine Consumption on Patients with Multiple Sclerosis-Related Fatigue. <i>Nutrients</i> , 2020, 12, 2262.	4.1	12
7	Effects of Alemtuzumab on (Auto)antigen-Specific Immune Responses. <i>Frontiers in Immunology</i> , 2020, 11, 563645.	4.8	7
8	Cytokine Storm in COVID-19â€Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper. <i>Frontiers in Immunology</i> , 2020, 11, 1648.	4.8	370
9	Patients With Epileptic Seizures and Multiple Sclerosis in a Multiple Sclerosis Center in Southern Germany Between 2003â€2015. <i>Frontiers in Neurology</i> , 2019, 10, 613.	2.4	22
10	We should focus more on finding therapeutic targets for the non-inflammatory damage in MS â€ No. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1274-1276.	3.0	0
11	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet, The</i> , 2018, 391, 1263-1273.	13.7	684
12	The Impact of Coffee and Caffeine on Multiple Sclerosis Compared to Other Neurodegenerative Diseases. <i>Frontiers in Nutrition</i> , 2018, 5, 133.	3.7	23
13	Functional Connectivity in Multiple Sclerosis: Recent Findings and Future Directions. <i>Frontiers in Neurology</i> , 2018, 9, 828.	2.4	66
14	The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 33-45.	1.8	65
15	Daytime sleepiness versus fatigue in patients with multiple sclerosis: A systematic review on the Epworth sleepiness scale as an assessment tool. <i>Sleep Medicine Reviews</i> , 2017, 32, 95-108.	8.5	58
16	Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1092-1103.	3.0	60
17	Increased immune reactivity to central nervous systemâ€derived naturally presented peptides in patients with active multiple sclerosis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 694-696.e7.	2.9	4
18	Effects of Sport Climbing on Multiple Sclerosis. <i>Frontiers in Physiology</i> , 2017, 8, 1021.	2.8	15

#	ARTICLE	IF	CITATIONS
19	Adaptive Immunity Is the Key to the Understanding of Autoimmune and Paraneoplastic Inflammatory Central Nervous System Disorders. <i>Frontiers in Immunology</i> , 2017, 8, 336.	4.8	25
20	Editorial: Induction of Central Nervous System Disease by the Adaptive Immune Response. <i>Frontiers in Immunology</i> , 2017, 8, 1218.	4.8	0
21	Fulminant Acute Ascending Hemorrhagic Myelitis Treated with Eculizumab. <i>Frontiers in Neurology</i> , 2017, 8, 345.	2.4	4
22	Suspected Perinatal Depression Revealed to be Hereditary Diffuse Leukoencephalopathy with Spheroids. <i>Journal of Movement Disorders</i> , 2017, 10, 59-61.	1.3	4
23	Influence of Formal Education on Cognitive Reserve in Patients with Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2016, 7, 46.	2.4	22
24	IL-3 promotes the development of experimental autoimmune encephalitis. <i>JCI Insight</i> , 2016, 1, e87157.	5.0	39
25	Myelin oligodendrocyte glycoprotein has a dual role in T cell autoimmunity against central nervous system myelin. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2016, 2, 205521731663099.	1.0	3
26	Identification of gene expression patterns critically involved in experimental autoimmune encephalomyelitis and multiple sclerosis. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 1211-1220.	2.4	24
27	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. <i>Annals of Neurology</i> , 2016, 79, 206-216.	5.3	315
28	Multiple Sclerosis. <i>Methods in Molecular Biology</i> , 2016, 1304, v-vi.	0.9	5
29	Benefit of ELISpot in early diagnosis of tuberculous meningoencephalitis: Case report and literature review. <i>ENeurologicalSci</i> , 2015, 1, 51-53.	1.3	2
30	Immune profile of an atypical EAE model in marmoset monkeys immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund's adjuvant. <i>Journal of Neuroinflammation</i> , 2015, 12, 169.	7.2	30
31	Oligoclonal bands predict multiple sclerosis in children with optic neuritis. <i>Annals of Neurology</i> , 2015, 77, 1076-1082.	5.3	61
32	Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases. <i>Frontiers in Immunology</i> , 2015, 6, 322.	4.8	84
33	Actively Induced Experimental Autoimmune Encephalomyelitis in Rats. <i>Methods in Molecular Biology</i> , 2014, 1304, 161-169.	0.9	8
34	Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). <i>Journal of Neurology</i> , 2014, 261, 1-16.	3.6	494
35	Activation of encephalitogenic T cells in a MOG-induced marmoset EAE model is regulated by linked suppression. <i>Journal of Neuroimmunology</i> , 2014, 275, 58.	2.3	0
36	Peripheral Blood Mononuclear Cells: Isolation, Freezing, Thawing, and Culture. <i>Methods in Molecular Biology</i> , 2014, 1304, 53-61.	0.9	85

#	ARTICLE	IF	CITATIONS
37	Treatment with atacicept enhances neuronal cell death in a rat model of optic neuritis. <i>Journal of Neuroimmunology</i> , 2014, 268, 58-63.	2.3	6
38	The Immune Pathogenesis of Multiple Sclerosis. <i>Journal of NeuroImmune Pharmacology</i> , 2013, 8, 857-866.	4.1	67
39	Autoantigen Conformation Influences Both B- and T-cell Responses and Encephalitogenicity. <i>Journal of Biological Chemistry</i> , 2012, 287, 17206-17213.	3.4	14
40	Re-expression of N-cadherin in remyelinating lesions of experimental inflammatory demyelination. <i>Experimental Neurology</i> , 2012, 237, 70-77.	4.1	14
41	Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis. <i>Archives of Neurology</i> , 2012, 69, 1259.	4.5	97
42	Statins: a revised appraisal for potential additional future treatment indications. <i>Arthritis Research and Therapy</i> , 2012, 14, 121.	3.5	4
43	Exogenous Schwann Cells Migrate, Remyelinate and Promote Clinical Recovery in Experimental Auto-Immune Encephalomyelitis. <i>PLoS ONE</i> , 2012, 7, e42667.	2.5	13
44	Experimental Autoimmune Encephalomyelitis. , 2012, , .		4
45	Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. <i>Lancet Neurology</i> , The, 2012, 11, 420-428.	10.2	152
46	Experimental Autoimmune Encephalomyelitis - Models, Disease Biology and Experimental Therapy. , 2012, , .		2
47	Therapeutic Efficacy of Intranasally Delivered Mesenchymal Stem Cells in a Rat Model of Parkinson Disease. <i>Rejuvenation Research</i> , 2011, 14, 3-16.	1.8	225
48	EAE: imperfect but useful models of multiple sclerosis. <i>Trends in Molecular Medicine</i> , 2011, 17, 119-125.	6.7	145
49	Neurodegeneration in MS and NMO: The Eye and the Blood. <i>Multiple Sclerosis International</i> , 2011, 2011, 1-2.	0.8	0
50	Cladribine. <i>Clinical Neuropharmacology</i> , 2011, 34, 28-35.	0.7	140
51	Progressive multifocal leukoencephalopathy. <i>Journal of Neuroimmunology</i> , 2011, 231, 73-77.	2.3	72
52	Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity. <i>Journal of Neuroimmunology</i> , 2011, 240-241, 52-57.	2.3	27
53	Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. <i>Neurology</i> , 2011, 77, 580-588.	1.1	286
54	Differential response to treatment of relapsingâ€“remitting multiple sclerosis with IFN-Î²: is there a dichotomy into T-helper-1 and -17 driven disease?. <i>Future Neurology</i> , 2010, 5, 481-484.	0.5	1

#	ARTICLE	IF	CITATIONS
55	Neurofilament ELISA validation. <i>Journal of Immunological Methods</i> , 2010, 352, 23-31.	1.4	86
56	A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2010, 362, 387-401.	27.0	2,314
57	Advanced Intercross Line Mapping Suggests That Ncf1 (Ean6) Regulates Severity in an Animal Model of Guillain-Barré Syndrome. <i>Journal of Immunology</i> , 2009, 182, 4432-4438.	0.8	18
58	Naturally Presented Peptides on Major Histocompatibility Complex I and II Molecules Eluted from Central Nervous System of Multiple Sclerosis Patients. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 2090-2101.	3.8	64
59	Autoimmune T cell responses to antigenic peptides presented by bronchoalveolar lavage cell HLA-DR molecules in sarcoidosis. <i>Clinical Immunology</i> , 2009, 133, 353-363.	3.2	63
60	The autoimmunity-related polymorphism PTPN22 1858C/T is associated with anti-titin antibody-positive myasthenia gravis. <i>Human Immunology</i> , 2009, 70, 540-542.	2.4	27
61	PO10-TU-40 Mode of action (MoA) of cladribine tablets: activity in lymphocytes and implications for treatment of multiple sclerosis (MS). <i>Journal of the Neurological Sciences</i> , 2009, 285, S206.	0.6	0
62	Characterization of the encephalitogenic immune response in a model of multiple sclerosis. <i>European Journal of Immunology</i> , 2008, 38, 299-308.	2.9	10
63	Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. <i>European Journal of Immunology</i> , 2008, 38, 2401-2411.	2.9	63
64	Gene expression analysis of normal appearing brain tissue in an animal model for multiple sclerosis revealed grey matter alterations, but only minor white matter changes. <i>Journal of Neuroimmunology</i> , 2008, 205, 10-19.	2.3	21
65	NCF1 gene and pseudogene pattern: association with parasitic infection and autoimmunity. <i>Malaria Journal</i> , 2008, 7, 251.	2.3	15
66	Multiple sclerosis and the CTLA4 autoimmunity polymorphism CT60: no association in patients from Germany, Hungary and Poland. <i>Multiple Sclerosis Journal</i> , 2008, 14, 153-158.	3.0	19
67	Myelin-Reactive Type B T Cells and T Cells Specific for Low-Affinity MHC-Binding Myelin Peptides Escape Tolerance in HLA-DR Transgenic Mice. <i>Journal of Immunology</i> , 2008, 181, 3202-3211.	0.8	18
68	The Use of Clinically Approved Small Particles of Iron Oxide (SPIO) for Labeling of Mesenchymal Stem Cells Aggravates Clinical Symptoms in Experimental Autoimmune Encephalomyelitis and Influences Their In Vivo Distribution. <i>Cell Transplantation</i> , 2008, 17, 923-941.	2.5	38
69	Î² Kinase 2/2 Deficiency Controls Expansion of Autoreactive T Cells and Suppresses Experimental Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2007, 179, 179-185.	0.8	46
70	Enhanced Glucocorticoid Receptor Signaling in T Cells Impacts Thymocyte Apoptosis and Adaptive Immune Responses. <i>American Journal of Pathology</i> , 2007, 170, 1041-1053.	3.8	43
71	FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. <i>Brain Research Bulletin</i> , 2007, 74, 307-316.	3.0	155
72	Notch1 and its ligand Jagged1 are present in remyelination in a T-cell- and antibody-mediated model of inflammatory demyelination. <i>Acta Neuropathologica</i> , 2007, 113, 195-203.	7.7	62

#	ARTICLE	IF	CITATIONS
73	Treatment of active secondary progressive multiple sclerosis with treosulfan. <i>Journal of Neurology</i> , 2007, 254, 884-889.	3.6	23
74	Identification of HLA-DRâ€‘bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. <i>Journal of Clinical Investigation</i> , 2007, 117, 3576-3582.	8.2	112
75	The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1587-1590.	2.8	5
76	Cortical Demyelination Can Be Modeled in Specific Rat Models of Autoimmune Encephalomyelitis and Is Major Histocompatibility Complex (MHC) Haplotype-Related. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 1137-1142.	1.7	77
77	Efficient presentation of myelin oligodendrocyte glycoprotein peptides but not protein by astrocytes from HLA-DR2 and HLA-DR4 transgenic mice. <i>Journal of Neuroimmunology</i> , 2006, 173, 23-34.	2.3	46
78	Differential Expression of Sonic Hedgehog Immunoreactivity During Lesion Evolution in Autoimmune Encephalomyelitis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 404-411.	1.7	46
79	Tolerance induction by bone marrow transplantation in a multiple sclerosis model. <i>Blood</i> , 2005, 106, 1875-1883.	1.4	62
80	CDR3 sequence preference of TCRBV8S2+ T cells within the CNS does not reflect single amino acid dependent avidity expansion. <i>Journal of Neuroimmunology</i> , 2005, 166, 47-54.	2.3	9
81	Peptide motif for the rat MHC class II molecule RT1.Da: similarities to the multiple sclerosis-associated HLA-DRB1*1501 molecule. <i>Immunogenetics</i> , 2005, 57, 69-76.	2.4	10
82	Differential Processing of Autoantigens in Lysosomes from Human Monocyte-Derived and Peripheral Blood Dendritic Cells. <i>Journal of Immunology</i> , 2005, 175, 5940-5949.	0.8	45
83	Diffusion Abnormality in Baloâ€™s Concentric Sclerosis: Clues for the Pathogenesis. <i>European Neurology</i> , 2005, 53, 42-44.	1.4	26
84	Experimental Autoimmune Encephalomyelitis (EAE): Lesion Visualization on a 3 Tesla Clinical Whole-body System after Intraperitoneal Contrast Injection. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2004, 176, 1549-1554.	1.3	4
85	Hyperphosphorylation and Aggregation of Tau in Experimental Autoimmune Encephalomyelitis. <i>Journal of Biological Chemistry</i> , 2004, 279, 55833-55839.	3.4	55
86	Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. <i>Neurology</i> , 2004, 63, 2381-2383.	1.1	69
87	MHC Class II Isotype- and Allele-Specific Attenuation of Experimental Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2004, 173, 2792-2802.	0.8	8
88	Analysis of Autoreactive CD4 T Cells in Experimental Autoimmune Encephalomyelitis after Primary and Secondary Challenge Using MHC Class II Tetramers. <i>Journal of Immunology</i> , 2004, 172, 2878-2884.	0.8	43
89	Mechanisms and Time Course of Neuronal Degeneration in Experimental Autoimmune Encephalomyelitis. <i>Brain Pathology</i> , 2004, 14, 148-157.	4.1	149
90	Lack of pathogenicity of immunodominant T and B cell determinants of the nicotinic acetylcholine receptor ðµ-chain. <i>Journal of Neuroimmunology</i> , 2004, 152, 44-56.	2.3	5

#	ARTICLE	IF	CITATIONS
91	MHC and non-MHC gene regulation of disease susceptibility and disease course in experimental inflammatory peripheral neuropathy. <i>Journal of Neuroimmunology</i> , 2004, 155, 73-84.	2.3	5
92	Escalating immunotherapy of multiple sclerosis. <i>Journal of Neurology</i> , 2004, 251, 1329-1339.	3.6	129
93	Immunogenicity of Torpedo acetylcholine receptor in the context of different rat MHC class II haplotypes and non-MHC genomes. <i>Immunogenetics</i> , 2004, 56, 61-64.	2.4	3
94	T cell epitope spreading to myelin oligodendrocyte glycoprotein in HLA-DR4 transgenic mice during experimental autoimmune encephalomyelitis. <i>Clinical Immunology</i> , 2004, 111, 53-60.	3.2	26
95	Ciliary Neurotrophic Factor Protects Retinal Ganglion Cells from Secondary Cell Death During Acute Autoimmune Optic Neuritis in Rats. <i>Brain Pathology</i> , 2004, 14, 378-387.	4.1	61
96	Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes. <i>Journal of Neuroimmunology</i> , 2003, 144, 28-37.	2.3	27
97	The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2003, 140, 177-187.	2.3	13
98	Modulation of neuronal activity by the endogenous pentapeptide QYNAD. <i>European Journal of Neuroscience</i> , 2003, 18, 2697-2706.	2.6	10
99	CD8+ Phagocyte Recruitment in Rat Experimental Autoimmune Encephalomyelitis. <i>American Journal of Pathology</i> , 2003, 163, 1517-1524.	3.8	25
100	Suppressive DNA Vaccination in Myelin Oligodendrocyte Glycoprotein Peptide-Induced Experimental Autoimmune Encephalomyelitis Involves a T1-Biased Immune Response. <i>Journal of Immunology</i> , 2003, 170, 1806-1813.	0.8	47
101	Methylprednisolone Increases Neuronal Apoptosis during Autoimmune CNS Inflammation by Inhibition of an Endogenous Neuroprotective Pathway. <i>Journal of Neuroscience</i> , 2003, 23, 6993-7000.	3.6	154
102	High Immunogenicity of Intracellular Myelin Oligodendrocyte Glycoprotein Epitopes. <i>Journal of Immunology</i> , 2002, 169, 548-556.	0.8	42
103	Long-term follow-up on a patient with incomplete POEMS syndrome undergoing high-dose therapy and autologous blood stem cell transplantation. <i>Blood</i> , 2002, 100, 2679-2680.	1.4	25
104	MHC Gene Related Effects on Microglia and Macrophages in Experimental Autoimmune Encephalomyelitis Determine the Extent of Axonal Injury. <i>Brain Pathology</i> , 2002, 12, 287-299.	4.1	30
105	Proton MR spectroscopy with metabolite-nulling reveals elevated macromolecules in acute multiple sclerosis. <i>Brain</i> , 2001, 124, 953-961.	7.6	94
106	Congenic mapping confirms a locus on rat chromosome 10 conferring strong protection against myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. <i>Immunogenetics</i> , 2001, 53, 410-415.	2.4	29
107	Transfer of myelin-specific cells deviated in vitro towards IL-4 production ameliorates ongoing experimental allergic neuritis. <i>Clinical and Experimental Immunology</i> , 2001, 123, 112-118.	2.6	9
108	Intra-CNS activation by antigen-specific T lymphocytes in experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2001, 113, 202-211.	2.3	11

#	ARTICLE	IF	CITATIONS
109	Polygenic control of autoimmune peripheral nerve inflammation in rat. Journal of Neuroimmunology, 2001, 119, 166-174.	2.3	10
110	Immunoglobulin isotypes reveal a predominant role of type 1 immunity in multiple sclerosis. Journal of Neuroimmunology, 2001, 121, 120-125.	2.3	38
111	MHC Class II-Regulated Central Nervous System Autoaggression and T Cell Responses in Peripheral Lymphoid Tissues Are Dissociated in Myelin Oligodendrocyte Glycoprotein-Induced Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2001, 166, 7588-7599.	0.8	52
112	T Cell Epitopes of Human Myelin Oligodendrocyte Glycoprotein Identified in HLA-DR4 (DRB1*0401) Transgenic Mice Are Encephalitogenic and Are Presented by Human B Cells. Journal of Immunology, 2001, 167, 7119-7125.	0.8	79
113	Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain, 2001, 124, 1114-1124.	7.6	159
114	Acute Neuronal Apoptosis in a Rat Model of Multiple Sclerosis. Journal of Neuroscience, 2001, 21, 6214-6220.	3.6	213
115	Genetics of rat neuroinflammation. Journal of Neuroimmunology, 2000, 107, 191-200.	2.3	32
116	Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 1689-1694.	7.1	40
117	Multiple Sclerosis and Chronic Autoimmune Encephalomyelitis. American Journal of Pathology, 2000, 157, 267-276.	3.8	854
118	Linkage Analysis of Myelin Oligodendrocyte Glycoprotein-Induced Experimental Autoimmune Encephalomyelitis in the Rat Identifies a Locus Controlling Demyelination on Chromosome 18. Human Molecular Genetics, 1999, 8, 2183-2190.	2.9	62
119	Allelic variations in rat MHC class II binding of myelin basic protein peptides correlate with encephalitogenicity. International Immunology, 1999, 11, 1981-1988.	4.0	22
120	Autoimmunity to Myelin Oligodendrocyte Glycoprotein in Rats Mimics the Spectrum of Multiple Sclerosis Pathology. Brain Pathology, 1998, 8, 681-694.	4.1	472
121	Late Onset Myasthenia Gravis: Follow-up of 113 Patients Diagnosed after Age 60. Annals of the New York Academy of Sciences, 1998, 841, 777-780.	3.8	34
122	Increased reactivity to myelin oligodendrocyte glycoprotein peptides and epitope mapping in HLA DR2(15)+ multiple sclerosis. European Journal of Immunology, 1998, 28, 3329-3335.	2.9	108
123	Vaccination with DNA Encoding an Immunodominant Myelin Basic Protein Peptide Targeted to Fc of Immunoglobulin G Suppresses Experimental Autoimmune Encephalomyelitis. Journal of Experimental Medicine, 1998, 187, 1543-1548.	8.5	93
124	MHC haplotype-dependent regulation of MOG-induced EAE in rats. Journal of Clinical Investigation, 1998, 102, 1265-1273.	8.2	224
125	Altered tumor growth factor β mRNA expression is associated with thymectomy-related clinical remission in myasthenia gravis. Journal of the Neurological Sciences, 1997, 151, 49-55.	0.6	9
126	Major histocompatibility complex haplotype RT1av1 is associated with relapsing/remitting experimental autoimmune encephalomyelitis. Transplantation Proceedings, 1997, 29, 1686-1689.	0.6	7

#	ARTICLE	IF	CITATIONS
127	Genetic analysis of inflammation, cytokine mRNA expression and disease course of relapsing experimental autoimmune encephalomyelitis in DA rats. <i>Journal of Neuroimmunology</i> , 1997, 80, 31-37.	2.3	31
128	T Cell Epitopes of the Acetylcholine Receptor and the Pathogenesis of Myasthenia Gravis. , 1997, , 119-126.		0
129	Thymectomy and azathioprine have no effect on the phenotype of CD4 T lymphocyte subsets in myasthenia gravis.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1993, 56, 46-51.	1.9	17
130	Specific immune complexes augment in vitro acetylcholine receptor-specific T cell proliferation. <i>Neurology</i> , 1993, 43, 583-583.	1.1	11
131	Neuroimmunology and Neurological Manifestations of COVID-19. , 0, , .		0